دورية أكاديمية
[FGFR2/3 in urothelial carcinoma].
| العنوان: | [FGFR2/3 in urothelial carcinoma]. |
|---|---|
| عنوان ترانسليتريتد: | FGFR2/3 im Urothelkarzinom. |
| المؤلفون: | Rose M; Institut für Pathologie, Uniklinik Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Deutschland.; Institut für Pathologie, Uniklinik RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Deutschland., Gaisa NT; Institut für Pathologie, Uniklinik Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Deutschland. Nadine.Gaisa@uniklinik-ulm.de.; Institut für Pathologie, Uniklinik RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Deutschland. Nadine.Gaisa@uniklinik-ulm.de. |
| المصدر: | Pathologie (Heidelberg, Germany) [Pathologie (Heidelb)] 2024 Sep 18. Date of Electronic Publication: 2024 Sep 18. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | German |
| بيانات الدورية: | Publisher: Springer Medizin Country of Publication: Germany NLM ID: 9918384887506676 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2731-7196 (Electronic) Linking ISSN: 27317188 NLM ISO Abbreviation: Pathologie (Heidelb) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Heidelberg, Germany] : Springer Medizin, [2022]- |
| References: | Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10(2):116–129. (PMID: 10.1038/nrc278020094046) Touat M, Ileana E, Postel-Vinay S, André F et al (2015) Targeting FGFR Signaling in Cancer. Clin Cancer Res 21(12):2684–2694. (PMID: 10.1158/1078-0432.CCR-14-232926078430) Liu X, Zhang W, Geng D, He J, Zhao Y et al (2014) Clinical significance of fibroblast growth factor receptor‑3 mutations in bladder cancer: a systematic review and meta-analysis. Genet Mol Res 13(1):1109–1120. (PMID: 10.4238/2014.February.20.1224634132) Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Diez de Medina GS et al (2001) Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158(6):1955–1959. (PMID: 10.1016/S0002-9440(10)64665-2113953711891972) Pal SK, Bajorin D, Dizman N, Hoffman-Censits J, Quinn DI et al (2020) Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. Cancer 126(11):2597–2606. (PMID: 10.1002/cncr.3280632208524) van Oers JM, Zwarthoff EC, Rehman I, Azzouzi AR, Cussenot O, Meuth M, Hamdy FC, Catto JW (2009) FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol 55(3):650–657. (PMID: 10.1016/j.eururo.2008.06.01318584939) Hahn NM, Bivalacqua TJ, Ross AE, Netto GJ, Baras A et al (2017) A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157. Clin Cancer Res 23(12):3003–3011. (PMID: 10.1158/1078-0432.CCR-16-226727932416) |
| تواريخ الأحداث: | Date Created: 20240918 Latest Revision: 20240918 |
| رمز التحديث: | 20240918 |
| DOI: | 10.1007/s00292-024-01363-0 |
| PMID: | 39292227 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. | تدمد: | 2731-7196 |
|---|---|
| DOI: | 10.1007/s00292-024-01363-0 |